In factor Xa inhibitor-related acute ICH, andexanet vs. usual care improved hemostatic efficacy but increased thrombotic events
- PMID: 39222512
- DOI: 10.7326/ANNALS-24-01365-JC
In factor Xa inhibitor-related acute ICH, andexanet vs. usual care improved hemostatic efficacy but increased thrombotic events
Abstract
Connolly SJ, Sharma M, Cohen AT, et al; ANNEXA-I Investigators. Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med. 2024;390:1745-1755. 38749032.
Conflict of interest statement
Comment on
-
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.N Engl J Med. 2024 May 16;390(19):1745-1755. doi: 10.1056/NEJMoa2313040. N Engl J Med. 2024. PMID: 38749032 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources